Lab guide · Neuropeptides
What Is N-Acetyl Selank Amidate? Modified Selank Analogue Peptide Research Overview
What is N-Acetyl Selank Amidate? It is Selank, the heptapeptide Thr-Lys-Pro-Arg-Pro-Gly-Pro, with an acetyl group on the N-terminus and an amide on the C-terminus. This guide covers its tuftsin-derived parent, the chemistry of the two end caps, and what has and has not been demonstrated for the capped form.
Key takeaways
- N-Acetyl Selank Amidate has the Selank sequence TKPRPGP with both termini capped, formula C35H60N12O9 and a mass of about 792.9 g/mol, 41 Da above Selank at 751.9 g/mol.
- Selank extends the tuftsin tetrapeptide TKPR with a Pro-Gly-Pro tail; the caps remove both terminal charges but leave the basic Lys and Arg side chains.
- N-terminal acetylation protects some peptides from DPP-IV and not others, and no comparison with Selank was found for this analogue.
- Evidence about Selank belongs to the parent compound and should not be transferred to the capped form.
What is N-Acetyl Selank Amidate?
So, what is N-Acetyl Selank Amidate? Selank is a heptapeptide, Thr-Lys-Pro-Arg-Pro-Gly-Pro, developed at the Institute of Molecular Genetics of the Russian Academy of Sciences by extending the immunomodulatory tetrapeptide tuftsin (TKPR) with a stabilising Pro-Gly-Pro tail, as described on the supplier product page; it is covered in What is Selank. N-Acetyl Selank Amidate (NA-Selank-NH2) keeps that sequence but caps both ends. It is a chemical derivative with no evidence base specific to it.
Research use only. This overview summarises published laboratory and animal research. Baltic Peptides supplies this compound for in-vitro and preclinical research by qualified researchers; it is not a medicine and is not for human or veterinary use.
Chemical structure and specifications
| Property | Selank | N-Acetyl Selank Amidate |
|---|---|---|
| Sequence | H-TKPRPGP-OH | Ac-TKPRPGP-NH2 |
| Formula | C33H57N11O9 | C35H60N12O9 |
| Average mass | 751.9 g/mol | 792.9 g/mol |
| Monoisotopic mass | 751.434 Da | 792.461 Da |
| Charge | N-terminal amine, Lys, Arg (+); carboxylate (−) | Lys and Arg remain; both terminal charges removed |
I confirmed the formulas and masses from the sequence. As with Semax, the caps add a net 41 Da. Because Selank carries two basic side chains (Lys and Arg), the capped form is still strongly cationic, and the caps change polarity less dramatically than for a more neutral peptide. No CAS number is listed for the capped form on the supplier page.
Discovery and research history
Tuftsin is a tetrapeptide derived from the Fc region of immunoglobulin G, and Selank was designed to extend and stabilise it. Selank is studied in Russia and is covered in its own article.
The capped form is a research-market analogue. The sources reviewed contain no original paper describing its synthesis or characterisation, so its history is that of Selank plus a generic chemical modification.
What terminal capping does, and does not, show
What is established in general
N-terminal blocking can protect peptides from DPP-IV and aminopeptidases. In one example, the N-terminally blocked Ac-GLP-1-(7-34)-amide was not degraded by DPP-IV over at least two hours (N-terminal acetylation protects GLP-1-(7-34)-amide from DPP-IV degradation).
What is not general
Acetylated peptides are not uniformly protected. In the classic rumen study, acetylation slowed breakdown but did not fully block it, and 72% of acetylated bradykinin was hydrolysed in an hour (Wallace (1992)). Selank already contains Pro residues at positions 3, 5 and 7, which are known to resist many peptidases, so the added benefit of capping is hard to predict. It has not been measured in the sources reviewed.
Main research areas
- Stability comparisons: serum and enzyme-incubation assays against Selank.
- Structure-activity work: effects of terminal charge removal on interaction with tuftsin-related targets.
- Analytical method development: confirming both caps by the +41 Da mass shift.
- Parent-compound research: Selank itself in rodent anxiety and immune models, see the Selank article.
What published studies actually show
| Evidence type | What is reported |
|---|---|
| Chemical facts | Sequence, formula, mass and caps are verifiable. |
| General capping studies | Protection from exopeptidases varies by peptide. |
| Selank literature | Studies of the parent peptide; not transferable to the capped form. |
| This analogue | No comparative published study of stability or activity was found. |
The persistence expected from the caps is a hypothesis for this peptide, not a result.
Scientific limitations and open questions
- No published comparison with Selank was found.
- Capping can protect, fail to protect or alter activity depending on the peptide.
- Selank already has proline-rich stability features, so the incremental effect is uncertain.
- It is not approved as a medicine.
Analytical and laboratory considerations
Mass spectrometry should show about 792.9 Da, confirming both caps, since Selank is 751.9 Da. Single-capped species would fall at about 750.9 Da (amide only) or 793.9 Da (acetyl only), so the intact mass separates them from the fully capped product only if resolution is sufficient. HPLC should resolve truncated sequences. Selank has no methionine, cysteine or tryptophan, so oxidation is a smaller concern than for Semax.
See how to store peptides and the guide to reading a peptide COA. Batch reports are on the COA page, and formats are on the N-Acetyl Selank Amidate product page.
Sources and further reading
- Acetylation of peptides inhibits their degradation by rumen micro-organisms (1992). Br J Nutr 68:365-372. PubMed
- N-terminal acetylation protects glucagon-like peptide GLP-1-(7-34)-amide from DPP-IV-mediated degradation retaining cAMP- and insulin-releasing capacity (2008). PubMed
- Rational design and delivery of engineered peptides (2026 review), on terminal capping. PMC
All Baltic Peptides products are supplied strictly for laboratory research use. They are not medicines, supplements or food and are not for human or animal use. This article summarises published research for educational purposes only and does not describe any use in people.
FAQ
Common questions
What is N-Acetyl Selank Amidate?
What is the molecular weight and formula of N-Acetyl Selank Amidate?
Where does Selank come from?
Is N-Acetyl Selank Amidate more stable than Selank?
How is it different from Selank?
How is it different from N-Acetyl Semax Amidate?
Is N-Acetyl Selank Amidate an approved medicine?
Keep reading
Related reading
N-Acetyl Selank Amidate
Current batches, formats and the COA.
What is Selank?
The uncapped parent peptide and its research literature.
What is N-Acetyl Semax Amidate?
The same double-cap strategy applied to Semax.
Research-grade N-Acetyl Selank Amidate, tested before it ships
Independent HPLC and mass spec results for every batch, dispatched from the EU.
